10x Genomics, Inc. (TXG) 2026 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Hello, everyone. Thank you for joining us, and welcome to the 10x Genomics third quarter 2026 earnings conference call. (Operator Instructions)

    各位好。感謝各位加入,歡迎參加 10x Genomics 2026 年第三季財報電話會議。(接線員指示)

  • I will now hand the conference over to Cassie Corneau, Senior Director and Head of Investor Relations and Strategic Finance. Please go ahead.

    現在我將把會議交給投資人關係與策略財務資深總監暨主管 Cassie Corneau。請開始。

  • Cassie Corneau - Senior Director, Head - Investor Relations & Strategic Finance

    Cassie Corneau - Senior Director, Head - Investor Relations & Strategic Finance

  • Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the third quarter ended September 30, 2026. If you have not received this news release or would like to be added to the company's distribution list, please send an e-mail to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call.

    謝謝,各位下午好。今天稍早,10x Genomics 公布了截至 2026 年 9 月 30 日止第三季的財務結果。若您尚未收到本新聞稿,或希望加入公司寄送名單,請寄電子郵件至 investors@10xgenomics.com。此次電話會議的網路直播存檔將於公司網站 10xgenomics.com 的「Investor」分頁提供,並在本次電話會議後至少保留 45 天。

  • Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements.

    在開始之前,我想提醒各位,管理層在本次電話會議中將發表若干聲明,這些聲明屬於聯邦證券法所定義的前瞻性陳述。這些陳述涉及重大風險與不確定性,可能導致實際結果或事件與預期存在重大差異,您不應過度依賴前瞻性陳述。

  • Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release 10x Genomics issued today and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.

    有關這些風險、不確定性以及可能導致結果出現差異之因素的更多資訊,載於 10x Genomics 今日發布的新聞稿,以及 10x Genomics 不時向美國證券交易委員會提交的文件與報告中。10x Genomics 不承擔、亦不表示有任何意圖或義務更新或修訂任何財務預測或前瞻性陳述,無論係因新資訊、未來事件或其他原因。

  • Joining the call today are Serge Saxonov, our CEO and Co-Founder; and Adam Taich, our Chief Financial Officer. We will host a question-and-answer session after our prepared remarks. We ask analysts to please keep to one question so that we may accommodate everyone in the queue.

    今天與會者包括我們的執行長暨共同創辦人 Serge Saxonov,以及我們的財務長 Adam Taich。在我們的準備發言之後,將進行問答環節。我們請分析師每次僅提一個問題,以便我們能夠讓佇列中的每位與會者都有機會發問。

  • With that, I will now turn the call over to Serge.

    接下來,我將把電話會議交給 Serge。

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Thanks, Cassie, and good afternoon, everyone. Revenue for the third quarter was $151 million, up 1% year-over-year. The biggest highlight was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we're incredibly excited to be putting instruments in customers' hands. The rest of the business also performed well, driven by continued strength in consumables. Adam will cover the financial results and outlook in more detail.

    謝謝你,Cassie,各位下午好。第三季營收為 1.51 億美元,年增 1%。最大的亮點是 Atera 開始商業出貨。市場對該平台的熱情持續升溫,我們也非常興奮能將儀器交到客戶手中。其餘業務表現同樣良好,主要受耗材持續強勁所帶動。Adam 將更詳細說明財務結果與展望。

  • Now stepping back, it's worth reflecting on this remarkable point in time as progress in AI is reshaping so much of the world. Many believe that AI's greatest promise is in accelerating science and advancing human health. We agree, and the key bottleneck is the data. Biology is incredibly complex. Capturing that complexity requires measuring biological systems at massive scale and high resolution. It requires measurements of molecules, cells and tissues across vast numbers of samples, conditions and context. This is precisely why we started 10x and why we have built our single cell and spatial technologies. And now as biology is entering this new era of AI and data maximalism, our business is positioned incredibly well to benefit and to be the key enabler of progress going forward.

    現在退一步來看,值得回顧這個非凡的時點:AI 的進展正在重塑世界的許多面向。許多人相信,AI 最大的承諾在於加速科學並推進人類健康。我們同意,而關鍵瓶頸在於資料。生物學極其複雜。要捕捉這種複雜性,需要以超大規模與高解析度量測生物系統。這需要在龐大的樣本數、條件與情境下,量測分子、細胞與組織。這正是我們創立 10x 的原因,也是我們打造單細胞與空間技術的初衷。而如今,隨著生物學進入 AI 與資料極大化的新時代,我們的業務定位極佳,將可受益並在未來成為推動進展的關鍵賦能者。

  • The success we're seeing with Atera is a powerful demonstration of this trend. The platform delivers whole transcriptome spatial profiling with single cell sensitivity at high throughput. It brings together molecular, cellular and tissue biology on a single instrument. By delivering its incredible capabilities at scale, Atera is both perfectly suited and critically necessary for this new AI-driven era of biology.

    我們在 Atera 上看到的成功,正是這一趨勢的有力證明。該平台以高通量提供具單細胞靈敏度的全轉錄體空間剖析。它在單一儀器上整合了分子、細胞與組織生物學。透過以規模化方式提供其卓越能力,Atera 不僅非常適合,也對這個由 AI 驅動的生物學新時代至關重要。

  • The extraordinary customer demand and momentum have continued to build since our last call. Our priority now is to ramp production, get instruments into customers' hands and help ensure their success. I've said before that we expected Atera to be the biggest product introduction in our history. And what we're seeing from customers is consistent with that expectation, whether judging by their enthusiasm for the platform, by the flow of orders or by the ambition of their plans. We're also encouraged by the strong interest in Catalyst Research Services, our internal service lab for running customer samples. In its first 5 months, more than 100 customers booked projects representing a wide variety of applications and use cases.

    自上次電話會議以來,客戶需求與動能持續攀升,且勢頭不減。我們目前的優先事項是提升產能、將儀器交付到客戶手中,並協助確保客戶成功。我先前曾說過,我們預期 Atera 會是公司史上規模最大的產品導入。而我們從客戶端看到的情況與此預期一致,無論是他們對平台的熱情、訂單流入,或是其計畫的雄心。我們也對 Catalyst Research Services(我們內部用於執行客戶樣本的服務實驗室)所獲得的強勁興趣感到鼓舞。在前 5 個月內,已有超過 100 位客戶預訂專案,涵蓋多元的應用與使用情境。

  • We're seeing extensive demand for Atera across universities, academic medical centers and biopharma. Customers are preparing to use the platform to generate data for AI models, whether for basic science, translational research or drug development. In addition to training AI models, customers are planning to deploy Atera across a wide range of applications and fields, including population scale studies, cell and tissue atlasing, studies of disease mechanisms and biomarker discovery.

    我們看到 Atera 在大學、學術醫學中心以及生物製藥領域均有廣泛需求。客戶正準備使用該平台為 AI 模型生成資料,無論是用於基礎科學、轉譯研究或藥物開發。除了訓練 AI 模型之外,客戶也計畫在多種應用與領域部署 Atera,包括族群尺度研究、細胞與組織圖譜建構、疾病機制研究以及生物標誌物探索。

  • Nearly all of the world's top 20 biopharma companies have now purchased Atera systems or services through Catalyst. As we mentioned previously, many pharmaceutical companies expect that spatial biology will fundamentally change how they approach drug discovery and development. We're hearing about applications across the entire drug development continuum from finding therapeutic targets to understanding mechanisms of action to assessing safety to predicting response in patients.

    全球前 20 大生物製藥公司中,幾乎都已透過購買 Atera 系統或透過 Catalyst 購買服務。如我們先前提到的,許多製藥公司預期空間生物學將從根本上改變其藥物探索與開發方式。我們聽到的應用涵蓋整個藥物開發連續體,從尋找治療標的、理解作用機制、評估安全性,到預測病患反應。

  • For example, we now have a growing arsenal of revolutionary medicines for treating cancer. The critical challenge is that most patients develop resistance and the mechanisms are not well understood. Many leading researchers are now planning to use Atera to address this challenge because Atera can provide an unparalleled view of the underlying cancer biology and of on-treatment effects.

    例如,我們現在擁有日益豐富的革命性藥物武器庫可用於治療癌症。關鍵挑戰在於多數病患會產生抗藥性,而其機制尚未被充分理解。許多領先研究人員正計畫使用 Atera 來應對此一挑戰,因為 Atera 能提供對癌症底層生物學以及治療中效應的無與倫比視角。

  • We built Atera as a long-duration upgradable platform to keep expanding what's possible in spatial biology. Our road map includes onboard slide preparation automation to enable true sample-in, data-out capability. It also includes RNA-protein multiomics and base-by-base sequencing for in-situ mutation detection. Together, these capabilities will enable customers to answer an even broader range of biological questions.

    我們將 Atera 打造成可長期使用、可升級的平台,以持續擴展空間生物學的可能性。我們的產品路線圖包含機載載玻片製備自動化,以實現真正的「樣本輸入、資料輸出」能力。也包含 RNA-蛋白多體學,以及逐鹼基定序以進行原位突變偵測。綜合而言,這些能力將使客戶能回答更廣泛的生物學問題。

  • Turning to Single Cell. Our customers continue to adopt our platforms for larger, more ambitious studies. Flex Apex is enabling a new generation of this work, especially in biopharma and translational research. Our recently introduced whole blood workflows are bringing single cell into applications that would previously have been inconceivable. Customers have shared enthusiasm for their ability to access troves of archival blood samples for retrospective single cell data generation. For prospective studies, the workflow stabilizes samples and simplifies processing at the point of collection, enabling use across a variety of clinical collection settings while dramatically reducing sample variability. Ultimately, these improvements enable more complete and consistent data sets that are critical for AI and for clinically related applications.

    接著談單細胞(Single Cell)。我們的客戶持續採用我們的平台來進行更大規模、更具企圖心的研究。Flex Apex 正在促成新一代的此類工作,特別是在生物製藥與轉譯研究領域。我們近期推出的全血工作流程,正將單細胞帶入過去難以想像的應用。客戶對其能夠存取大量封存血液樣本、用於回溯性單細胞資料生成的能力表達了高度熱情。對於前瞻性研究,該工作流程可在採集端穩定樣本並簡化處理,使其能在多種臨床採集場景中使用,同時大幅降低樣本變異性。最終,這些改進可帶來更完整且更一致的資料集,這對 AI 以及臨床相關應用至關重要。

  • Our single cell solutions have long been at the epicenter of the perturbation experiments that are now fueling AI biology models. Furthermore, we're now seeing increasing demand for multimodal solutions driven by the value of measuring more biology from the same cell. And lately, we're seeing customers build up their infrastructure, investing in automation to expand the scale of these experiments.

    我們的單細胞解決方案長期以來一直處於擾動實驗的核心,而這些實驗如今正為 AI 生物學模型提供動力。此外,我們也看到對多模態解決方案的需求日益增加,這是由於能從同一個細胞量測更多生物學資訊所帶來的價值。而最近,我們看到客戶正在建置其基礎設施,投資自動化以擴大這些實驗的規模。

  • Our new Flex Apex CRISPR workflow builds on the scalability, robustness and sensitivity of Flex Apex for perturbation studies. Combined with our Proteintech Genomics panels, the largest single-cell protein panels available, researchers get the richest data per cell for model development. And our newest GEM-X Multiome configuration captures gene expression alongside the regulatory elements that control it.

    我們全新的 Flex Apex CRISPR 工作流程,建立在 Flex Apex 於擾動研究中的可擴展性、穩健性與靈敏度之上。結合我們的 Proteintech Genomics panel(目前可用的最大單細胞蛋白 panel),研究人員可為模型開發取得每個細胞最豐富的資料。而我們最新的 GEM-X Multiome 配置,能在捕捉基因表達的同時,捕捉控制其表達的調控元件。

  • Taken together, we believe our menu of multimodal solutions delivers the best approach for generating valuable mechanistic data critical for drug target discovery and predictive models of biology.

    綜合而言,我們相信我們的多模態解決方案組合,提供了產生有價值機制性資料的最佳方法,而這些資料對於藥物標的發現與生物學預測模型至關重要。

  • As the scale of data enabled by these products grows exponentially, analysis can become an even greater bottleneck. We see that as both a challenge and an opportunity. And with that in mind, this quarter, we announced Sentira, our new cloud analysis platform. Sentira is designed to help customers turn large complex biological data into experimental conclusions using agentic AI, all in a seamless integrated experience. Researchers can explore their results and iterate rapidly without having to build or manage the underlying computing infrastructure.

    隨著這些產品所促成的資料規模呈指數成長,分析可能成為更大的瓶頸。我們將其視為挑戰,同時也是機會。基於此,本季我們宣布推出 Sentira——我們全新的雲端分析平台。Sentira 旨在協助客戶透過代理式 AI,在無縫整合的體驗中,將龐大且複雜的生物資料轉化為實驗結論。研究人員可以探索結果並快速迭代,而無需建置或管理底層運算基礎設施。

  • We have announced the initial capabilities of the platform with a lot more to come in the future. Sentira Spatial uses NVIDIA-accelerated computing to reduce processing of Atera and Xenium data from hours to minutes. Sentira Single Cell brings agentic analysis to Chromium data powered by Anthropic's Claude. Researchers can ask questions in natural language, review proposed analyses and examine the methods and code behind the results in an editable notebook. Together, these capabilities give more scientists the computational power and analytical tools to turn increasingly complex data sets into biological understanding.

    我們已公布該平台的初始功能,未來還會有更多推出。Sentira Spatial 使用 NVIDIA 加速運算,將 Atera 與 Xenium 資料的處理時間從數小時縮短至數分鐘。Sentira Single Cell 由 Anthropic 的 Claude 驅動,將代理式分析帶到 Chromium 資料上。研究人員可用自然語言提問、審閱建議的分析,並在可編輯的筆記本中檢視結果背後的方法與程式碼。這些能力結合起來,讓更多科學家擁有運算能力與分析工具,將日益複雜的資料集轉化為生物學理解。

  • And as we have said, in addition to being an accelerator of data analysis, AI represents a structural tailwind for the demand for our products. It is still very early days, but the effects of AI demand are being felt across many areas of our business. Today, most significant biological data generation efforts are conceived at least in part with the goal of training AI models. And when researchers set out to build AI models of biology, they usually think in terms of multiomics, single cell and spatial, which usually means our technologies. This is not surprising because as I mentioned earlier, we built our technologies precisely to measure biological systems comprehensively at massive scale and high resolution.

    此外,正如我們所說,除了加速資料分析之外,AI 也代表著對我們產品需求的結構性順風。目前仍處於非常早期的階段,但 AI 需求的影響已在我們業務的多個領域浮現。如今,多數重要的生物資料生成工作,至少部分是以訓練 AI 模型為目標而構思。而當研究人員著手建立生物學 AI 模型時,通常會以多組學、單細胞與空間為思考框架,而這通常意味著我們的技術。這並不令人意外,因為如我先前提到的,我們打造這些技術正是為了以大規模與高解析度,全面量測生物系統。

  • Across different segments thought leaders are converging on the idea that we need large-scale data collection on an industrial scale. We have previously talked about some of the projects that have been publicly announced, such as the ones from Cancer Research Institute, ARC Institute and CZI Biohub. These efforts have all been progressing and scaling up. For example, recently, Biohub has been outlining its ambitions toward profiling hundreds of billions of cells to build predictive AI models of life.

    在不同領域中,思想領袖正逐漸匯聚到一個觀點:我們需要以工業規模進行大規模資料收集。我們先前談到過一些已公開宣布的專案,例如 Cancer Research Institute、ARC Institute 與 CZI Biohub 的專案。這些工作都在持續推進並擴大規模。例如,近期 Biohub 正在闡述其雄心:對數千億個細胞進行剖析,以建立可預測的生命 AI 模型。

  • At the same time, governments across the world are looking to invest in sovereign AI capabilities in health care and biology. There is often a strong case to be made for training models based on unique samples and profiles of local populations. These plans naturally translate into mandates to collect multiomics, single cell and spatial data. We believe these priorities could support programs to generate large biological data sets and models around the world.

    同時,全球各國政府也在尋求投資於醫療保健與生物學領域的主權 AI 能力。以本地族群的獨特樣本與特徵來訓練模型,往往具有充分的理由。這些計畫自然會轉化為收集多組學、單細胞與空間資料的任務要求。我們相信,這些優先事項可在全球支持產生大型生物資料集與模型的計畫。

  • In biopharma, there continues to be rapid growth in AI-focused investments. Much of the initial AI investment has focused on chemistry on designing and making molecules. As we have noted in the past, we believe the next arguably larger opportunity lies in understanding the biology, identifying new therapeutic targets and predicting how patients will respond to treatment. This requires a much deeper view of cells and tissues, and that is precisely the information our technologies enable customers to generate.

    在生物製藥領域,以 AI 為重點的投資仍在快速成長。初期的 AI 投資多聚焦於化學領域,用於設計與製造分子。正如我們過去所指出的,我們相信下一個、可說更大的機會在於理解生物學、辨識新的治療標的,以及預測病患對治療的反應。這需要對細胞與組織有更深入的視角,而這正是我們的技術能讓客戶產生的資訊。

  • We're seeing similar momentum among techbio companies, where we are the predominant vendor of choice for single cell and spatial data generation. This category is expanding beyond drug development companies to include diagnostics companies looking to use their large collections of patient samples to generate training data for AI models. While it's still very early, these developments strengthen our conviction that we are at the beginning of an exponential trend in the scale of AI-driven data generation.

    我們也在 techbio 公司中看到類似的動能;在單細胞與空間資料生成方面,我們是其主要首選供應商。此類別正從藥物開發公司擴展到診斷公司,後者希望利用其大量病患樣本收藏,為 AI 模型生成訓練資料。儘管仍處於非常早期階段,這些發展強化了我們的信念:我們正處於 AI 驅動資料生成規模呈指數趨勢的起點。

  • Finally, we're continuing to make progress with our clinical strategy. Our newly announced collaboration with Fred Hutch adds to the partnerships we have formed with some of the leading medical centers around the world. As a reminder, we're focused on generating evidence to establish the clinical utility of our single cell and spatial technologies in oncology and autoimmunity. Our team is also making strong progress standing up an internal CLIA lab with the goal of launching it next year. While these efforts are still early, we're encouraged by our learnings and by the potential of Single Cell and Spatial in patient care.

    最後,我們在臨床策略方面也持續取得進展。我們新近宣布與 Fred Hutch 的合作,進一步擴充了我們與全球一些頂尖醫學中心所建立的夥伴關係。提醒一下,我們的重點是產生證據,以建立我們單細胞與空間技術在腫瘤學與自體免疫領域的臨床效用。我們的團隊也在積極推進建立內部 CLIA 實驗室,目標是在明年推出。雖然這些工作仍在早期階段,但我們對所獲得的學習以及單細胞與空間技術在病患照護中的潛力感到鼓舞。

  • So coming back to where we started. We're at the beginning of an era in which AI will bring extraordinary advances in biology, and our products are delivering the data that is necessary for that progress. In executing our company mission, we have spent more than a decade building the assets, capabilities and expertise to put us in a position to capitalize on the opportunities created by this era. And our strong financial profile gives us the ability to realize the full potential of these opportunities. We're excited for the road ahead.

    回到我們一開始談到的重點。我們正處於一個 AI 將在生物學帶來非凡進展的時代開端,而我們的產品正在提供推動這些進展所必需的資料。在執行公司使命的過程中,我們已投入十餘年打造資產、能力與專業,使我們處於能把握此一時代所創造機會的位置。而我們強健的財務體質,讓我們有能力實現這些機會的全部潛力。我們對前方的道路充滿期待。

  • With that, I will now turn the call over to Adam.

    接下來,我將把電話會議交給 Adam。

  • Adam Taich - Chief Financial Officer

    Adam Taich - Chief Financial Officer

  • Thanks, Serge. Unless otherwise noted, all growth rates referenced reflect year-over-year comparisons. Revenue for the third quarter was $150.7 million, representing 1% growth over the prior year period. Total consumables revenue was up 5%, with growth in both Single Cell and Spatial. Single Cell consumables revenue grew 1%, supported by double-digit growth in reaction volumes given strong demand for Flex Apex. Spatial consumables revenue grew 16%, driven primarily by Xenium consumables. It is especially encouraging to see Xenium continue to perform well even in anticipation of Atera. This demonstrates the strong momentum behind Spatial and reinforces our conviction in the opportunity for Atera.

    謝謝你,Serge。除非另有說明,所提及的所有成長率皆為年對年比較。第三季營收為 1.507 億美元,較去年同期成長 1%。耗材總營收成長 5%,單細胞與空間兩者皆有成長。單細胞耗材營收成長 1%,在 Flex Apex 強勁需求帶動下,反應量呈現兩位數成長。空間耗材營收成長 16%,主要由 Xenium 耗材帶動。尤其令人鼓舞的是,即便在 Atera 即將推出的預期下,Xenium 仍持續表現良好。這顯示空間業務背後的強勁動能,並強化我們對 Atera 機會的信心。

  • Total instrument revenue declined 43% with Chromium instrument revenue down 23% and Spatial instrument revenue down 57%, both primarily driven by a lower number of units sold. As anticipated, the decline in Spatial instruments reflects customers moderating purchases of our Visium and Xenium products in anticipation of Atera.

    儀器總營收下滑 43%,其中 Chromium 儀器營收下滑 23%,空間儀器營收下滑 57%,兩者主要皆由銷售台數減少所致。如預期所示,空間儀器的下滑反映客戶在 Atera 推出前,放緩對我們 Visium 與 Xenium 產品的採購。

  • Turning to the rest of the P&L. Gross margin increased to 75%, up from 67% in the prior year period. The increase in gross margin was primarily driven by lower inventory write-downs and changes in product mix. Total operating expenses were $129 million for the quarter as compared to $132.5 million in the prior year period. The decrease was primarily driven by lower personnel and lab equipment expenses, partially offset by higher litigation expenses. We ended the quarter with $576 million in cash, cash equivalents and marketable securities, up $94 million year-over-year and up $24 million sequentially.

    接著看損益表其餘項目。毛利率提升至 75%,高於去年同期的 67%。毛利率上升主要由較低的存貨減記以及產品組合變化所帶動。本季營業費用總額為 1.29 億美元,去年同期為 1.325 億美元。下降主要由人員與實驗室設備費用降低所致,部分被較高的訴訟費用所抵銷。本季末我們持有的現金、約當現金及有價證券為 5.76 億美元,年增 9,400 萬美元,季增 2,400 萬美元。

  • Turning to our outlook for the rest of the year. We are raising our full year outlook and now expect 2026 revenue to be in the range of $625 million to $635 million, up from $610 million to $630 million. Excluding nonrecurring revenue related to patent litigation settlements in both 2026 and 2025, this represents 4% to 6% growth over the full year 2025. The increase reflects our third quarter performance, stronger-than-anticipated spatial consumables and a higher Atera shipment outlook for the year.

    接著談談我們對今年剩餘時間的展望。我們上調全年展望,現在預期 2026 年營收將落在 6.25 億至 6.35 億美元之間,高於先前的 6.10 億至 6.30 億美元。若排除 2026 年與 2025 年皆包含之與專利訴訟和解相關的一次性營收,這相當於相較 2025 全年成長 4% 至 6%。這次上調反映了我們第三季的表現、優於預期的空間(spatial)耗材,以及今年 Atera 出貨展望的提高。

  • Our Atera production ramp is progressing well as we've leveraged our experience building complex instruments like Xenium. As a result, we now expect to ship approximately 50 Atera instruments by year-end, up from our previous expectation of approximately 40. Additionally, as Atera instrument shipments ramp in the fourth quarter, we expect gross margins to step down sequentially. Our disciplined focus on cash generation and expense management has strengthened our financial position, giving us even greater capacity to invest for growth and capitalize on the significant opportunities ahead.

    我們的 Atera 量產爬坡進展順利,因為我們運用過去打造如 Xenium 等複雜儀器的經驗。因此,我們現在預期在年底前出貨約 50 台 Atera 儀器,高於先前預期的約 40 台。此外,隨著第四季 Atera 儀器出貨加速,我們預期毛利率將按季下滑。我們在現金創造與費用管理上的紀律性聚焦,強化了財務狀況,使我們更有能力投資成長並把握前方的重大機會。

  • With that, I'll turn the call back to Serge.

    接下來我把電話交回給 Serge。

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Thanks, Adam. Before we open it up for questions, I want to thank the entire 10 times team. Atera embodies so much of what makes this company special, the ambition to take on problems that seem out of reach, the persistence to work through them and the commitment to get the details right. Bringing it to life has drawn on talent and dedication from across the company, united by our mission to advance human health through a deeper understanding of biology. I'm incredibly proud of this team and grateful for everything you do. Seeing what we can accomplish together gives me even greater conviction in the future we're building.

    謝謝,Adam。在開放提問之前,我想感謝整個 10x 團隊。Atera 體現了這家公司之所以特別的許多特質:敢於挑戰看似遙不可及的問題的雄心、克服困難的韌性,以及把細節做到位的承諾。讓它成真仰賴全公司各處的才華與投入,並由我們的使命凝聚在一起——透過更深入理解生物學來推進人類健康。我為這個團隊感到無比自豪,也感謝你們所做的一切。看到我們能一起完成的成果,讓我對我們正在打造的未來更具信心。

  • With that, we will now open up for questions. Operator?

    接著,我們現在開放提問。接線員?

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Tycho Peterson.

    Tycho Peterson。

  • Lauren Timmins - Analyst

    Lauren Timmins - Analyst

  • Hey, team. This is Lauren on for Tycho. I just have one around consumables. So they came in about 5% year-over-year this quarter and are averaging around 8% for the year. I guess what has to happen to get above 10% for consumables overall? Does that ultimately require single cell to accelerate? Or do you think spatial on its own can get return to double-digit growth, especially once Atera pull-through ramps?

    嗨,團隊。我是 Lauren,代 Tycho 發問。我只有一個關於耗材的問題。所以本季耗材年增大約 5%,全年平均大約 8%。我想問的是,要讓整體耗材成長率超過 10% 需要發生什麼?最終是否需要單細胞(single cell)加速成長?或者你們認為僅靠空間(spatial)就能回到雙位數成長,尤其是在 Atera 的拉動效應(pull-through)加速之後?

  • Adam Taich - Chief Financial Officer

    Adam Taich - Chief Financial Officer

  • Sure. Thanks, Lauren. Yes, I think the way that you -- you still want to answer the question on your own. I think continuing to drive the reaction volumes that we have and seeing price stabilize in single cell would certainly be one element of it. More than that, though, we feel extremely confident about the growth trajectory for our Spatial consumables business.

    當然。謝謝你,Lauren。是的,我想你——你其實已經在某種程度上回答了這個問題。我認為持續推動我們的反應量(reaction volumes),以及看到單細胞的價格趨於穩定,肯定會是其中一個要素。但更重要的是,我們對空間耗材業務的成長軌跡非常有信心。

  • So even with the Atera launch, which we had announced back in April and started shipping instruments in September, we still have quite a strong spatial consumables number for Q3. That momentum is still quite strong here going into Q4, and we're starting to ship Atera consumables here in Q4 as well. And so I think that gives us confidence in the future, and we're feeling really good about where we are in Spatial consumables and consumables overall going forward.

    即使在 Atera 上市的情況下——我們在 4 月就已宣布,並於 9 月開始出貨儀器——第三季我們的空間耗材數字仍然相當強勁。這股動能在進入第四季時依然很強,而且我們也將在第四季開始出貨 Atera 耗材。因此,這讓我們對未來更有信心;我們對空間耗材以及整體耗材接下來的表現感覺非常好。

  • Operator

    Operator

  • Kyle Mikson with Canaccord Genuity

    Canaccord Genuity 的 Kyle Mikson。

  • Kyle Mikson - Equity Analyst

    Kyle Mikson - Equity Analyst

  • Yeah, hey, guys. Thanks for the questions. Just on the CapEx side of Spatial. So 50 Ateras by year-end, that's good to hear. And just talking to KOLs, it seems like you got a very small number out in the field maybe like 5 or less. So is 50 to -- I guess I'll call it 40 to 50 placements per quarter a good way to think about the ramp? Or could there be upside to that next year?

    是的,嗨,各位。謝謝讓我提問。我想問空間業務的資本支出(CapEx)。年底前 50 台 Atera,這很高興聽到。而且跟一些 KOL 交流後,看起來你們在現場的台數可能很少,大概 5 台或更少。所以,把每季 40 到 50 台的裝機(placements)當作爬坡的思考方式是否合理?或者明年是否可能有上行空間?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Kyle, thanks for the question. And yes, you're right. So like as we said, we expect to ship about 50 units by the end of this year. And there's a lot of work in terms of scaling up production, getting the sort of the manufacturing order and actually also getting the instruments to our customers, right, installing it, training customers, making them successful. And kind of as we extrapolate into next year, obviously, we've said before, demand is not the bottleneck.

    Kyle,謝謝你的問題。是的,你說得沒錯。如同我們所說,我們預期今年年底前出貨約 50 台。在擴大產能方面有很多工作要做,包括把製造流程與產能規劃到位,另外也要把儀器交付給客戶——也就是安裝、訓練客戶、讓他們成功使用。而當我們推估到明年時,顯然我們之前也說過,需求不是瓶頸。

  • We have lots and lots of orders, but the, sort of, the production capacity and the installed capacity is going to be more of the binding constraint going into next year. We want to make sure that we are making our customers maximally successful. That's our North Star. And so as we kind of come out of this year, as we go into next year, kind of, thinking about 50 a quarter between those constraints is about the right number.

    我們有非常非常多的訂單,但進入明年時,生產能力與已安裝的產能(installed capacity)將會是更主要的限制因素。我們希望確保客戶能夠取得最大的成功。這是我們的北極星指標(North Star)。因此,當我們走出今年、進入明年,在這些限制條件之間,每季大約 50 台的規模大致是合理的數字。

  • Operator

    Operator

  • Subbu Nambi, Guggenheim Securities.

    Guggenheim Securities 的 Subbu Nambi。

  • Subbu Nambi - Equity Analyst

    Subbu Nambi - Equity Analyst

  • Hi, guys. This is Thomas on for Subbu. The top 20 biopharmas that you noted using Atera, I guess just what share have bought their own system in terms of placing an order? And then can you just talk about the difference in utilization between this group and then those using CRS? For those using CRS, just what's holding them back before buying their own system?

    嗨,各位。我是 Thomas,代 Subbu 發問。你們提到前 20 大生物製藥公司正在使用 Atera,我想問其中有多少比例已經下單購買自有系統?另外,你們能否談談這一群客戶與使用 CRS 的客戶之間,在使用率(utilization)上的差異?對於使用 CRS 的客戶而言,在購買自有系統之前,是什麼因素讓他們有所遲疑?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yes. No. So, I haven't broken out kind of the split between who is buying instruments and who is putting in orders through the CRS. And as far as the, kind of, the reasons, you have to remember that we just announced Atera back in April. This is a brand-new platform. No one was anticipating those capabilities. People are extremely excited about it. They have been -- as we've been, kind of, talking about, they've been collecting the budgets and putting in funding.

    是的。不過,我沒有把哪些是在買儀器、哪些是透過 CRS 下單的拆分數據整理出來。至於原因,你必須記得我們是在 4 月才宣布 Atera。這是一個全新的平台。沒有人預期會有這些能力。大家都非常興奮。而且如同我們一直在談的,他們一直在籌措預算並取得資金。

  • At the same time, it makes sense that people would also want to test the system and test to see the data for themselves on their own kind of samples. Of course, it's a mix. But yes, overall, we're looking really good. The interest in both CRS and in purchasing their own instruments right out of the gate for a platform that no one was even aware of until just a few months ago is really, really remarkable.

    同時,人們也會想先測試系統,並用他們自己的樣本親自看看數據,這也很合理。當然,這會是混合的情況。但總體而言,我們的狀況非常好。對於一個幾個月前大家甚至還不知道的平台,市場對 CRS 以及直接購買自有儀器的興趣都非常、非常驚人。

  • Operator

    Operator

  • Casey Woodring, JPMorgan.

    JPMorgan 的 Casey Woodring。

  • Marta Zaremba - Analyst

    Marta Zaremba - Analyst

  • Hi. This is Marta Zaremba on for Casey Woodring. So you mentioned strong Atera orders so far. So can you give us more color on the backlog for the instrument, both quantitative but also qualitative, perhaps on the types of customers that are ordering and really like the mix between and pharma? And any other color you can share.

    嗨。我是 Marta Zaremba,代 Casey Woodring 發問。你們提到目前 Atera 訂單很強勁。能否就儀器的在手訂單(backlog)提供更多細節,包括量化與質化的資訊,例如下單客戶的類型,以及學研與藥廠(pharma)之間的組合?以及任何你們能分享的其他資訊。

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yes, No. Thanks for the question. We've said before, we don't really share our backlog numbers or our order numbers. And I would again kind of emphasize with Atera, especially the binding constraint here is not orders at all. It is kind of our scaling up of manufacturing operations and also our capacity to install and train customers. And that's going to be the case next quarter. It's going to be the case as we head into next year as well.

    是的,不會。謝謝你的提問。我們之前也說過,我們不太會分享我們的積壓訂單(backlog)數字或訂單數量。我也想再次強調,就 Atera 而言,這裡真正的約束因素完全不是訂單。而是我們擴大製造營運的能力,以及我們為客戶安裝並進行培訓的產能。下個季度也會是這樣。進入明年時也同樣如此。

  • As far as the question around kind of the mix, it's been a really healthy mix all across our customer base. We've mentioned before, and we've seen the pattern continue that there's, relatively speaking, more interest from biopharma when it comes to Atera, which is really encouraging. And it's also kind of across the ecosystem, big pharma and biotech and service providers as well. Very nice broad set of applications from like very basic science to, as I talked about extensively, applications for training AI models to a lot of translational research, like really looking at figuring out mechanisms of action, looking for drug targets, looking for biomarkers, seeing kind of response to therapy to be able to predict patient response. So really, really great reception from like the entire ecosystem.

    至於你問到的組合(mix)問題,我們在整個客戶群中看到的是非常健康的組合。我們之前提過,而且我們也看到這個趨勢持續:相對而言,在 Atera 方面,生物製藥客戶的興趣更高,這非常令人鼓舞。而且這也涵蓋整個生態系,包括大型藥廠、生技公司以及服務供應商。應用面也非常廣,從非常基礎的科學研究,到如我先前詳細談到的用於訓練 AI 模型的應用,再到大量的轉譯研究,例如真正去釐清作用機制、尋找藥物標的、尋找生物標記、觀察對治療的反應,以便能預測病患反應。所以,整個生態系的反應都非常、非常好。

  • Operator

    Operator

  • Matt Larew, William Blair.

    Matt Larew,William Blair。

  • Christian Starzynski - Analyst

    Christian Starzynski - Analyst

  • Hello.

    你好。

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Hey Matt, we can hear you.

    嗨 Matt,我們聽得到你。

  • Christian Starzynski - Analyst

    Christian Starzynski - Analyst

  • It's actually Christian on for Matt. Congrats on the Atera launch. Just recognizing that it's still like very early, wondering how -- since Atera is now finally in customers' hands, how has the initial like user experience compared with your internal expectations going into the launch? Wondering if you've learned any -- what are your learnings from the first installations and customer runs? And has there been any unexpected, whether it be like workflow challenges or areas where performance or usage actually exceeded internal expectations?

    其實是 Christian 代替 Matt 上線。恭喜 Atera 上市。我知道現在仍然非常早期,但想請教——既然 Atera 現在終於已經交到客戶手上,上市後初期的使用者體驗和你們內部在上市前的預期相比如何?想了解你們從第一批安裝與客戶實際跑樣中學到了什麼?以及是否有任何出乎意料之處,不論是工作流程上的挑戰,或是某些效能或使用情況其實超出內部預期?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yeah. Good question, Christian. So yes, a couple of points to make here. First of all, as you pointed out, we're very, very early in this launch. We started shipping towards the end of September. So this is very early. And with the first shipment, especially, we want to make sure we take our time and really go through the pieces appropriately as we're getting these systems to our customers as we're standing them up and training them.

    是的。好問題,Christian。這裡我想提幾點。首先,正如你指出的,我們在這次上市上仍然非常、非常早期。我們是在 9 月底左右開始出貨。所以現在真的非常早。而且特別是第一批出貨,我們希望確保放慢腳步,花時間把各個環節都妥善處理:把系統交付給客戶、完成建置並對客戶進行培訓。

  • As it happens in every launch, especially the launch of this complexity, part of what you have to expect is the unexpected, which is partially why we've been very deliberate with how we're rolling these out. So far, it's been great. Like we -- definitely a lot of learnings. You very quickly get a lot of learnings. But I don't think anything that's incongruent with our expectations at all.

    如同每一次產品上市,尤其是這種複雜度的上市,你必須預期會有意料之外的狀況,這也是我們為何在推進這些部署時一直非常審慎、循序漸進。到目前為止,一切都很棒。確實有很多學習。你會很快就獲得很多學習。但我不認為有任何事情與我們的預期不一致。

  • I would also say that the team has been making a lot of progress even since the time we announced the platform back in the spring. And it's been really great to see the progress. And one of the ways it's been manifesting itself is that the data keeps getting better, like the specs of the platform keep increasing and improving. And the feedback from customers on that has been really phenomenal. They were really, really happy with what they saw back in the spring. They are really blown away with what they're seeing now.

    我也想說,自從我們在春季宣布這個平台以來,團隊一直在取得很大的進展。看到這些進展真的很棒。其中一個具體呈現方式是:數據表現持續變得更好,平台規格也持續提升與改善。客戶對此的回饋非常出色。他們在春季看到時就已經非常、非常滿意。而他們現在看到的,更是讓他們非常驚艷。

  • Operator

    Operator

  • Puneet Souda, Leerink.

    Puneet Souda,Leerink。

  • Michael Almisry - Analyst

    Michael Almisry - Analyst

  • Hi, everyone you have Michael on for Puneet. I think I wanted to pivot the conversation to Single Cell. Could you offer any color on the Apex transition, like how far along we are there? I know you've also talked about Apex being the most -- or the Flex being the most popular product. I'm curious if that's now tied to being the majority of the reactions sold? And how much of this adoption is really led by pharma versus your academic customer base?

    各位好,我是 Michael,代替 Puneet。我想把話題轉到單細胞(Single Cell)。你們能否談談 Apex 的轉換進度,例如目前進行到什麼程度?我也知道你們提過 Apex 是最——或是 Flex 是最受歡迎的產品。我想了解這是否也意味著它現在已經占反應(reactions)銷售的大多數?另外,這波採用成長主要是由藥廠帶動,還是由學術客戶群帶動?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yes, good question. So Apex has been doing really well. And in fact, to your last point, especially with biopharma, really has been scaling really rapidly. So overall, we do -- we feel really good about Single Cell and all the different market dynamics, like I talked about earlier around AI, around translational applications around biopharma adoption. We -- this has been our strategy over the course of this year, really to keep driving Apex adoption and to keep driving reaction growth. And that's what we have been seeing. This past quarter was again an example of that, really, really strong reaction growth. And yes, Apex is definitely headed towards being kind of that sort of majority of reactions in our Chromium portfolio.

    是的,好問題。Apex 的表現非常好。而且事實上,呼應你最後一點,特別是在生物製藥端,規模擴張得非常快。整體而言,我們對單細胞以及各種市場動態都感到非常樂觀,例如我先前提到的 AI、轉譯應用,以及生物製藥採用。今年以來,這一直是我們的策略:持續推動 Apex 的採用,並持續推動反應量成長。而我們確實看到了這樣的結果。本季度再次是一個例子,反應量成長非常、非常強勁。是的,Apex 的確正朝著在我們 Chromium 產品組合中成為反應量占比的多數方向前進。

  • Now, as we've always said, obviously, Apex on a per reaction basis is lower priced. And so as we're going through that transition, especially as we, kind of, lean into that transition, it does create some pressure on top line revenue. And so that's what we've been managing throughout this year, and things have been going well according to plan. And I would say even in some aspects, the adoption has been even deeper than we were anticipating.

    當然,如同我們一直說的,Apex 以每次反應計價的單價較低。因此在我們推進這個轉換的過程中,特別是當我們某種程度上更積極地投入這個轉換時,確實會對營收(top line revenue)帶來一些壓力。這也是我們今年一直在管理的部分,而目前進展都很符合計畫。我也會說,在某些面向上,採用深度甚至比我們原先預期的還要更高。

  • Operator

    Operator

  • Mason Carrico, Stephens.

    Mason Carrico,Stephens。

  • Benjamin Mee - Equity Analyst

    Benjamin Mee - Equity Analyst

  • Hi, good afternoon. This is Ben on for Mason. For Atera, I was wondering if you'd be able to provide what the mix of whole transcriptome versus select runs is today or just early interest in those options? And how do you see that evolving over the next 12 months?

    嗨,午安。我是 Ben,代替 Mason。關於 Atera,我想請教你們是否能提供目前全轉錄組(whole transcriptome)與選擇性(select)跑樣的組合占比,或至少談談市場對這些選項的早期興趣?以及你們如何看待未來 12 個月這個組合的演變?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yeah, Ben, thanks. Really great question. So one of the learnings, what we've been seeing is there's a huge interest in whole transcriptome. That's what people are, by and large, focusing on to extent that has exceeded our expectations. I think this is a function of maybe a number of things, but I think one of the big ones is just we're sort of in the AI era of data maximalism. People really want to be able to get as much information as they can for building these models, for being able to build models in the future as well.

    好的,Ben,謝謝。非常好的問題。我們的一個學習是:市場對全轉錄組有非常大的興趣。大體上大家的重點都放在全轉錄組,而且這個程度超出我們的預期。我認為這可能是多個因素造成的,但其中一個主要因素是:我們正處於 AI 時代的「資料極大化」(data maximalism)。人們真的希望能取得盡可能多的資訊,用來建立這些模型,也用來在未來建立模型。

  • And of course, that's great for our business in a whole number of ways is standardize people to pretty consistent workflows. It also removes what was really the biggest throttler to Xenium adoption. Xenium has been doing really well. But nevertheless, from day one, it was always somewhat constrained by the fact that customers needed to select panels or create their own custom panels. And with the whole transcriptome, people can just go. And so that has been one of the really nice learnings as well, still very early days, but whole transcriptome is really the dominant way that people are using it.

    當然,這在很多方面對我們的業務都很有利,因為它能讓大家採用相當一致、標準化的工作流程。它也消除了過去對 Xenium 採用最大的限制因素。Xenium 的表現一直很好。但即便如此,從第一天起,它總是受到一個因素的限制:客戶需要選擇 panel,或建立自己的客製 panel。而有了全轉錄組,大家就可以直接開始。因此這也是一個非常好的學習;雖然仍是非常早期,但全轉錄組確實是目前人們使用它的主流方式。

  • Benjamin Mee - Equity Analyst

    Benjamin Mee - Equity Analyst

  • Dominant way that people are using it.

    人們使用它的主要方式。

  • Operator

    Operator

  • Albert Hu, Citi.

    Albert Hu,花旗。

  • Albert Hu - Analyst

    Albert Hu - Analyst

  • Hey, perfect. Thanks for taking the question. I don't know if I missed this, but did you guys break out the Atera placements in 3Q? And then maybe just on gross margins. You mentioned a quarter-to-quarter step down in 4Q. So I guess at what point post the Atera launch should we expect GMs to recover to the prelaunch levels? Is there a year from now? Is it longer? I appreciate all the color here.

    嗨,太好了。謝謝讓我提問。我不確定是不是我漏聽了,但你們在第三季(3Q)有把 Atera 的裝機/部署(placements)單獨拆分出來揭露嗎?另外想問一下毛利率。你們提到第四季(4Q)毛利率會較上一季下滑。所以我想問,Atera 上市之後大概到什麼時間點,我們應該預期毛利率能回升到上市前的水準?是一年後嗎?還是更久?也謝謝你們提供這些細節。

  • Adam Taich - Chief Financial Officer

    Adam Taich - Chief Financial Officer

  • Yes. Sure, I can take that. We didn't specifically say, but we sold a couple. If you think about what's in the revenue number for Q3, it's a couple of Ateras, pretty much coincided with when we put the release out in late September. From a gross margin perspective, yes, the 75% that we printed for Q3, when you look at instruments and from a mix perspective, extremely light, right, because we've got the transition dynamics going on where Xenium instruments understandably and sort of as we forecasted and guided slowed down.

    是的。當然,我可以回答。我們沒有特別說明,但我們確實賣出了幾台。如果你看第三季的營收數字,裡面包含了幾台 Atera,時間點大致與我們在九月底發布產品消息相吻合。就毛利率而言,是的,我們第三季公布的 75% 毛利率,從儀器以及產品組合的角度來看,儀器占比非常低,對吧?因為我們正處於轉換期的動態之中,Xenium 儀器的銷售如同我們預測與指引所說,確實放緩了。

  • And Atera just with the 2 units out there into the field didn't pick up that slack. So 75% gross margin isn't exactly where we think we'll be in Q4. As we start to work more Ateras out in the field, anticipate gross margins will be in the low to mid-60s for Q4. So that's essentially what we'll see for the next quarter.

    而 Atera 目前只有 2 台在外部客戶端,尚不足以補上這個缺口。因此,75% 的毛利率並不是我們認為第四季會達到的水準。隨著我們開始把更多 Atera 推向市場,我們預期第四季毛利率會落在 60% 出頭到中段(low to mid-60s)。

  • I think it's really important to note as we think about 2027 though, the overall gross margin profile of the Atera platform is superior to that of the Xenium platform. So both the instruments and the consumables are notably higher. And so while we do anticipate, as Serge mentioned earlier, we're going to be working through the rate-limiting step for us right now is production, installation and customer success.

    不過我認為在展望 2027 年時,有一點非常重要:Atera 平台的整體毛利率結構優於 Xenium 平台。無論是儀器還是耗材,毛利率都明顯更高。因此,雖然我們確實預期——如 Serge 先前提到——我們將持續推進;但目前對我們而言的瓶頸步驟其實是生產、安裝以及客戶成功(customer success)。

  • It isn't orders. So as we're working through in the first half of next year and into the second half of next year, instrument placements and installations, we'd anticipate margins for 2027 will most likely come in lower than where they are. And obviously, we'll provide more color when we provide guidance early next year, but they most likely come in lower just it's going to be an instrument heavy year, and consumables will start to ramp during the course of the year.

    不是訂單。所以當我們在明年上半年、以及進入明年下半年持續推進儀器的裝機與安裝時,我們預期 2027 年的毛利率很可能會低於目前水準。當然,我們會在明年初提供指引時給更多細節,但毛利率很可能會較低,原因是那將會是一個以儀器為主的年度,而耗材會在年度進程中開始逐步放量。

  • Operator

    Operator

  • David Westenberg, Piper Sandler.

    David Westenberg,Piper Sandler。

  • Skye Gilbert - Analyst

    Skye Gilbert - Analyst

  • Hi, This is Skye on for Dave. Can you talk a little bit more about the Sentira and the early customer workflows you're seeing it enable? Like how do you expect it to create value commercially? And any color on whether it's through software revenue, higher Chromium usage or just broader platform adoption would be helpful. Thanks.

    嗨,我是代 Dave 提問的 Skye。你能否再多談一些 Sentira,以及你們看到它在早期客戶工作流程中所帶來的改變?例如你們預期它在商業上如何創造價值?以及能否補充一下,這個價值主要會來自軟體收入、更高的 Chromium 使用量,或是更廣泛的平台採用?這些資訊都會很有幫助。謝謝。

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yeah, No, great question. So I mentioned we released our new platform, Sentira just recently with, kind of, combining cloud-based compute provision with agentic analysis. Now, stepping back, right, for instance like the beginning of history since our first products, going back to the start of genomics, the biggest bottleneck that people would point to in getting value out of our products is data analysis. And we've invested a lot over the years in data analysis, but it's nevertheless, it's oftentimes a bottleneck, a constraint, especially for people that are kind of not -- don't have the computational sort of expertise with a lot of bioinformatics kind of background.

    好的,這是個很好的問題。如我提到的,我們最近發布了新平台 Sentira,某種程度上是把雲端運算資源的供應(cloud-based compute provision)與代理式(agentic)分析結合在一起。回過頭來看,從我們第一代產品開始、甚至回到基因體學的早期,人們在談到如何從我們的產品中取得價值時,最大的瓶頸一直是資料分析。多年來我們在資料分析上投入很多,但即便如此,它仍然常常是瓶頸與限制,特別是對於那些不具備運算專長、或沒有深厚生物資訊背景的人而言。

  • So Sentira is meant to address that bottleneck. And to a first order, the most important thing about Sentira is that -- is always our customers and accelerate the rest of our business, right? It helps our customers process the data and be able to get insights from that. Now, it also provides a means for us to deliver value and charge for software. And over time, that will create more opportunities for us and more revenue potential. But at this point, it is really about streamlining the experience for our customers and really, kind of, accelerating the use of all the other products that we sell.

    Sentira 的目的就是要解決這個瓶頸。從最核心的角度來看,Sentira 最重要的意義在於——始終是服務我們的客戶,並加速我們其他業務的成長,對吧?它能幫助客戶處理資料並從中取得洞見。同時,它也提供我們一種交付價值並對軟體收費的方式。隨著時間推進,這將為我們帶來更多機會與更大的營收潛力。但就目前而言,它真正的重點是讓客戶體驗更順暢,並且在某種程度上加速客戶使用我們所銷售的其他所有產品。

  • Operator

    Operator

  • Doug Schenkel, UBS.

    Doug Schenkel,瑞銀(UBS)。

  • Sean Garden - Analyst

    Sean Garden - Analyst

  • This is Sean Gardner on for Doug. Just wanted to go back to Spatial consumables. So it grew 16% again in Q3, 16% in Q2 as well. And you kind of previously characterized Q3 as the peak of the Atera-related transition. So just based on what you saw in this quarter, is the performance consistent with that expectation? I guess, should we think about the underlying Spatial consumables business returning to growth sequentially in Q4? Or is that improvement more likely to materialize in '27? And then as Atera placements ramp generally, how should we be thinking about timing and trajectory of consumables pull-through?

    我是代 Doug 提問的 Sean Gardner。我想回到 Spatial 耗材。第三季又成長了 16%,第二季也是 16%。而你們先前曾將第三季描述為與 Atera 相關的轉換期高峰。所以就你們本季看到的情況而言,這樣的表現是否符合你們的預期?也就是說,我們是否應該預期 Spatial 耗材的基本面業務在第四季會出現季增回到成長?還是說這樣的改善更可能在 2027 年才會顯現?另外,隨著 Atera 裝機量整體爬升,我們應該如何看待耗材拉動(pull-through)的時間點與成長軌跡?

  • Adam Taich - Chief Financial Officer

    Adam Taich - Chief Financial Officer

  • Yes. Sure. I can take that. Thank you for the question. Yes, I would say, by and large, the performance in Q3 was modestly better than what we had anticipated on the Spatial consumables in particular. Obviously, it was better than we'd anticipated in other areas as well. The Xenium pull-through continues to be quite strong. And it's an incredible platform and customers are still quite pleased with it. One of the dynamics we're looking at when you think about it in the context of our guide, we certainly anticipate that Spatial consumables in Q4 will still be double digits for sure. That's embedded in the guidance.

    是的,當然。我可以回答。謝謝你的提問。是的,我會說,整體而言,第三季 Spatial 耗材的表現比我們原先預期略好一些。顯然,其他領域的表現也比我們預期更好。Xenium 的耗材拉動仍然相當強勁。這是一個非常出色的平台,客戶也仍然對它非常滿意。從我們指引的脈絡來看,其中一個我們在觀察的動態是:我們確實預期第四季 Spatial 耗材仍會維持雙位數成長,這是確定的。這已經反映在指引之中。

  • We'll have a full quarter of Atera consumables shipments. And then we're keeping a close eye just on Xenium pull-through in particular, Visium to a lesser degree. But we still think it's going to be a very strong quarter for us on Spatial consumables and give us incredible momentum going into 2027.

    我們也將有一整季的 Atera 耗材出貨。此外,我們也會密切關注 Xenium 的耗材拉動,Visium 的部分相對次要一些。但我們仍然認為第四季對我們的 Spatial 耗材而言會是非常強勁的一季,並為我們邁入 2027 年帶來極佳的動能。

  • Operator

    Operator

  • There are no further questions at this time. This concludes today's call. Thank you for attending. You may now disconnect.

    目前沒有其他問題。今天的電話會議到此結束。感謝各位參與。您現在可以斷線。